Heron Bay Capital Management Takes $6.25 Million Position in Exelixis, Inc. $EXEL

Posted by Francis Steltz on Aug 22nd, 2026

Heron Bay Capital Management acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) during the second quarter, Holdings Channel.com reports. The firm acquired 114,799 shares of the biotechnology company’s stock, valued at approximately $6,246,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in EXEL. BlackRock Inc. acquired a new position in Exelixis during the second quarter valued at approximately $1,581,991,000. AQR Capital Management LLC lifted its stake in shares of Exelixis by 48.8% in the fourth quarter. AQR Capital Management LLC now owns 13,658,388 shares of the biotechnology company’s stock worth $598,647,000 after buying an additional 4,477,029 shares during the last quarter. Norges Bank acquired a new stake in shares of Exelixis in the fourth quarter worth $106,460,000. Bank of New York Mellon Corp bought a new stake in shares of Exelixis during the 2nd quarter worth $107,803,000. Finally, UBS Group AG boosted its holdings in shares of Exelixis by 100.1% during the 3rd quarter. UBS Group AG now owns 2,655,069 shares of the biotechnology company’s stock worth $109,654,000 after buying an additional 1,328,087 shares during the period. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Exelixis

In related news, Director Sue Gail Eckhardt sold 9,812 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $50.14, for a total value of $491,973.68. Following the completion of the transaction, the director directly owned 16,079 shares in the company, valued at approximately $806,201.06. This represents a 37.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mary C. Beckerle sold 9,812 shares of Exelixis stock in a transaction on Monday, August 10th. The stock was sold at an average price of $53.66, for a total transaction of $526,511.92. Following the sale, the director owned 16,079 shares in the company, valued at $862,799.14. This represents a 37.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 67,000 shares of company stock valued at $3,404,652. Company insiders own 2.60% of the company’s stock.

Exelixis Stock Up 0.7%

Shares of EXEL opened at $54.08 on Friday. The stock’s 50-day moving average price is $54.26 and its 200 day moving average price is $48.56. The firm has a market capitalization of $13.40 billion, a price-to-earnings ratio of 17.01, a P/E/G ratio of 1.60 and a beta of 0.44. Exelixis, Inc. has a 12-month low of $33.76 and a 12-month high of $57.57.

Exelixis (NASDAQ:EXEL – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.06. Exelixis had a return on equity of 42.17% and a net margin of 35.33%.The company had revenue of $628.69 million during the quarter, compared to the consensus estimate of $636.40 million. During the same quarter last year, the company earned $0.75 EPS. The company’s quarterly revenue was up 10.6% on a year-over-year basis. Equities research analysts expect that Exelixis, Inc. will post 3.18 EPS for the current year.

Analyst Ratings Changes

EXEL has been the topic of several recent analyst reports. Citizens Jmp lifted their target price on shares of Exelixis from $50.00 to $55.00 and gave the stock a “market outperform” rating in a report on Wednesday, June 24th. Weiss Ratings raised Exelixis from a “buy (b)” rating to a “buy (a-)” rating in a research report on Tuesday, August 11th. Barclays raised their price target on Exelixis from $45.00 to $49.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 14th. Stifel Nicolaus lifted their price objective on Exelixis from $47.00 to $51.00 and gave the stock a “hold” rating in a research note on Thursday, August 6th. Finally, Zacks Research cut Exelixis from a “hold” rating to a “strong sell” rating in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $50.07.

Check Out Our Latest Report on Exelixis

Exelixis Profile

(Free Report)

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.